No 02 2010

Novo Nordisk has outlined its strategic ambitions for 2030 at a Capital Markets Day in London, targeting more than five multi-blockbuster launches by 2030 and more than DKK 150 billion in risk-adjusted pipeline sales in 2035. The company also aims to serve more than 60 million patients globally by 2030.

Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.

The Life Science Cluster turns ten. But instead of looking in the rearview mirror, let's look at why life science will matter more over the next decade.

More than 40% of women in the US say their health has limited their career, and the share rises to 66% among women who cannot get the care they need, according to a new Gallup survey conducted in partnership with Pivotal.

The European Medicines Agency's human medicines committee (CHMP) has adopted a positive opinion recommending marketing authorisation for Novo Nordisk's Frehemgo (denecimig) for haemophilia A, with or without inhibitors, in adults and children. The company says it is the first factor VIIIa mimetic offering once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen.

The US Food and Drug Administration (FDA) has accepted and granted Priority Review to Alexion, AstraZeneca's Rare Disease unit, for efzimfotase alfa as a treatment for patients with hypophosphatasia (HPP) aged 2 years and older.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Pepaxti (melflufen) be extended to earlier lines of multiple myeloma treatment, a move that would significantly widen the drug's eligible patient population.